Market Incident

Public · Developing

AI compiled from Infoway · 3 analyzed stories

Carlyle and PAI Partners agree to sell pharma company Theramex to Cinven

Carlyle and PAI Partners agreed to sell Theramex, a London-based specialty pharmaceutical company focused on women's health, to rival private equity firm Cinven. The companies did not disclose financial terms, though the Financial Times reported the deal was worth 2.6 billion euros, or $2.9 billion.

Published:

Updated:

What happened

Carlyle and PAI Partners agreed to sell Theramex, a London-based company focused on women’s health, to private equity firm Cinven. The companies did not disclose the price. A report put it at €2.6 billion, and Cinven is seeking €1.5 billion in debt to help fund the purchase.

Global impact / market context

The borrowing is part of how Cinven plans to pay for the purchase. The reports give different levels of certainty about the price: the companies did not disclose it, while a report cited €2.6 billion. No market reaction is provided.

What to watch

  1. Check whether the companies disclose the sale price; it would clarify the reported €2.6 billion figure.
  2. Check whether Cinven secures the sought €1.5 billion in debt; it would show whether this planned funding is obtained.
  3. Check for further updates on the agreed sale; they could clarify the status of the purchase.

Affected assets

  • Theramex

Evidence